Array BioPharma Licenses Gastric Cancer Compound To Singapore's ASLAN; ASLAN Will Bring To POC And Find Partner
This article was originally published in The Pink Sheet Daily
Executive Summary
Partnership enables Array to focus its resources on two compounds that are furthest in development and gain expertise in the Asian market.
You may also be interested in...
ASLAN Completes Series A Funding For $12 Mn; Eyes More Financing Options With Spiraling Portfolio
MUMBAI - Singapore-based discovery research start-up ASLAN Pharmaceuticals reached a major milestone as it completed its Series A financing of $12 million. The fund will be utilized to develop the first set of in-licensed compounds by ASLAN
Roche's Challenge With Herceptin Gastric Cancer Claim Will Be Companion Dx Use
As with Herceptin in breast cancer, the drug is approved simultaneously with a companion diagnostic to measure HER2 levels in gastric cancer patients, but the use of the test is different.
ASLAN CEO Carl Firth On A New Paradigm for Drug Development In Asia: An Interview With PharmAsia News
Asia continues to increase in importance for global clinical trial programs. Big pharmas such as Novartis and AstraZeneca are building up their own R&D sites while Eli Lilly and Pfizer are creating virtual R&D networks, taking advantage of the large naïve patient population and other efficiencies in Asia to accelerate drug development.